药物减轻成人原发性IgA肾病蛋白尿的研究进展

摘要/Abstract

摘要： 目的：免疫球蛋白A肾病（IgA nephropathy，IgAN）是世界范围内最常见的原发性肾小球疾病，但其临床症状、病理表现和预后不同。蛋白尿是影响IgAN患者预后的重要因素之一，对IgAN蛋白尿的治疗已从最初的随访观察发展到肾素-血管紧张素受体拮抗剂联合支持治疗，再到免疫抑制剂和靶向治疗。本文拟就如何通过药物减少IgAN患者蛋白尿及根据病理分型制定治疗方案进行综述，以期为临床治疗IgAN提供参考。

关键词: font-size:medium, ">IgA肾病；蛋白尿；免疫抑制剂；病理分型

Abstract: IgA nephropathy（IgAN） is the most common primary glomerular disease， but its clinical manifestation and prognosis are different. Proteinuria is one of the important factors affecting the prognosis of patients with IgA nephropathy. The treatment of proteinuria in IgA nephropathy has developed from initial follow-up observation to renin-angiotensin system blockade（RASB） combined support therapy and then to immunosuppressant and targeted therapy. This article reviews how to reduce proteinuria in IgA nephropathy by drugs and according to the pathological classification to specify the treatment plan， so as to provice reference for clinical treatment.

Key words: font-size:medium, ">IgA nephropathy； Proteinuria； Immunosuppressant； Pathological type

中图分类号:

禹乐佳, 梁栋, 刘云启. 药物减轻成人原发性IgA肾病蛋白尿的研究进展[J]. 中国医药导刊, 2020, 22(6): 401-406.

YU Lejia, LIANG Dong, LIU Yunqi. Research Progress on Drugs Reducing Proteinuria in Adult Primary IgA Nephropathy[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2020, 22(6): 401-406.

参考文献 33

[1]	Chen S， Yin Q， Ren S， et al. A comparison of the effectiveness of cyclophosphamide， leflunomide， corticosteroids， or conservative management alone in patients with IgA nephropathy：a retrospective observational study [J]. Sci Rep， 2018， 8(1)：13662.
[2]	Inker LA， Mondal H， Greene T， et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy：an individual-patient meta-analysis[J]. Am J Kidney Dis， 2016， 68(3)：392-401.
[3]	Tesar V， Troyanov S， Bellur S， et al. Corticosteroids in IgA nephropathy：a retrospective analysis from the VALIGA study [J]. J Am Soc Nephrol， 2015， 26(9)：2248-2258.
[4]	Coppo R. Clinical and histological risk factors for progression of IgA nephropathy：an update in children， young and adult patients [J]. J Nephrol， 2017， 30(3)：339-346.
[5]	Bellur SS， Roberts ISD， Troyanov S， et al. Reproducibility of the Oxford classification of immunoglobulin A nephropathy， impact of biopsy scoring on treatment allocation and clinical relevance of disagreements：evidence from the VALidation of IGA study cohort [J]. Nephrol Dial Transplant， 2019， 34(10)：1681-1690.
[6]	Trimarchi， H， Barratt J， Cattran DC， et al. Oxford classification of IgA nephropathy 2016：an update from the IgA Nephropathy Classification Working Group[J]. Kidney Int， 2017， 91(5)：1014-1021.
[7]	Lai KN， Leung JC， Tang SC. The treatment of IgA nephropathy [J]. Kidney Dis (Basel)， 2015， 1(1)：19-26.
[8]	Pozzi C， Sarcina C， Ferrario F. Treatment of IgA nephropathy with renal insufficiency [J]. J Nephrol， 2016， 29(4)：551-558.
[9]	Zhang Z， Jiang SM， Ma YP， et al. Expression of the intrarenal angiotensin receptor and the role of renin-angiotensin system inhibitors in IgA nephropathy [J]. Mol Cell Biochem， 2019， 453(1-2)：103-110.
[10]	Yoon CY， Chang TI， Kang EW， et al. Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy [J]. Ann Med， 2017， 49(3)：217-229.
[11]	Lin Y， Jia J， Guo Y， et al. Corticosteroid for IgA nephropathy：are they really therapeutic? [J]. Am J Nephrol， 2018， 47(6)：385-394.
[12]	Coppo R. Corticosteroids in IgA nephropathy：lessons from recent studies [J]. J Am Soc Nephrol， 2017， 28(1)：25-33.
[13]	Rauen T， Fitzner C， Eitner F， et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy [J]. J Am Soc Nephrol， 2018， 29(1)：317-325.
[14]	Fellstrom BC， Barratt J， Cook H， et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN)：a double-blind， randomised， placebo-controlled phase 2b trial [J]. Lancet， 2017， 389(10084)：2117-2127.
[15]	Stangou M， Ekonomidou D， Giamalis P， et al. Steroids and azathioprine in the treatment of IgA nephropathy [J]. Clin Exp Nephrol， 2011， 15(3)：373-380.
[16]	Hogg RJ， Bay RC， Jennette JC， et al. Randomized controlled trial of mycophenolate mofetil in children， adolescents， and adults with IgA nephropathy [J]. Am J Kidney Dis， 2015， 66(5)：783-791.
[17]	Hou JH， Le WB， Chen N， et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions：a randomized controlled trial [J]. Am J Kidney Dis， 2017， 69(6)：788-795.
[18]	Yang P， Wang Q， Xie C， et al. Efficacy and safety of agents in IgA nephropathy：an update network meta-analysis [J]. Kidney Blood Press Res， 2018， 43(6)：1890-1897.
[19]	Qin W， Zhong X， Fan JM， et al. External suppression causes the low expression of the Cosmc gene in IgA nephropathy [J]. Nephrol Dial Transplant， 2008， 23(5)：1608-1614.
[20]	Xie L， Tan C， Fan J， et al. Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy [J]. Int Urol Nephrol， 2013， 45(2)：571-579.
[21]	Zhang Y， Luo J， Hu B， et al. Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy：a meta-analysis [J]. J Int Med Res， 2018， 46(8)：3236-3250.
[22]	Fan L， Liu Q， Liao Y， et al. Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome：a prospective， multicenter clinical trial [J]. Int Urol Nephrol， 2013， 45(2)：459-468.
[23]	Song YH， Cai GY， Xiao YF， et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy：a meta-analysis [J]. BMC Nephrol， 2017， 18(1)：61.
[24]	Liu H， Xu X， Fang Y， et al. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy：a prospective randomized controlled trial [J]. Int Med， 2014， 53(7)：675-681.
[25]	Liu LJ， Yang YZ， Shi SF， et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy：a randomized controlled trial [J]. Am J Kidney Dis， 2019， 74(1)：15-22.
[26]	Wang Z， Yu C， Zhou LN， et al. Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria [J]. Biol Pharm Bull， 2017， 40(11)：1833-1838.
[27]	Myette JR， Kano T， Suzuki H， et al. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy [J]. Kidney Int， 2019， 96(1)：104-116.
[28]	Lafayette RA， Canetta PA， Rovin BH， et al. A randomized， controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction [J]. J Am Soc Nephrol， 2017， 28(4)：1306-1313.
[29]	Markham A. Fostamatinib：first global approval [J]. Drugs， 2018， 78(9)：959-963.
[30]	Ring T， Pedersen BB， Salkus G， et al. Use of eculizumab in crescentic IgA nephropathy：proof of principle and conundrum? [J]. Clin Kidney J， 2015， 8(5)：489-491.
[31]	Rosenblad T， Rebetz J， Johansson M， et al. Eculizumab treatment for rescue of renal function in IgA nephropathy [J]. Pediatr Nephrol， 2014， 29(11)：2225-2228.
[32]	Tumlin， JA， Madaio MP， Hennigar R， Idiopathic IgA nephropathy：pathogenesis， histopathology， and therapeutic options [J]. Clin J Am Soc Nephrol， 2007， 2(5)：1054-1061.
[33]	Bellur， SS， Lepeytre F， Vorobyeva O， et al. Evidence from the Oxford classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy[J]. Kidney Int， 2017， 91(1)：235-243.

快速检索引用检索图表检索高级检索